Berg focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg is well positioned for rapid commercialization of its intellectual capital.
A hallmark feature of cancer is the Warburg effect characterized by a preferential utilization of glucose for molecular sustainability of the oncogenic phenotype. Utility of the Berg Interrogative Biology™ technology platform has enabled unraveling of key factors in the control of metabolic network differential between a healthy cell and a cancer cell microenvironment. The company has successfully harnessed the ability of BPM 31510 to recapitulate mitochondrial oxidative phosphorylation and normalize metabolic networks to create an anti-cancer effect. A topical formulation of BPM 31510 for the treatment of skin cancers has demonstrated safety and efficacy in Phase I/II trials. The endogenous nature of the BPM 31510 technology is key to the molecule's safety profile and absence of adverse effects in clinical trials thus far. This phenomenon has recapitulated an ongoing Phase I dose escalation clinical trial using an intravenous formulation of 31510 in the treatment of solid tumors.
Moreover, Berg has successfully leveraged the ability of the Berg M3™ Technology in leveraging the BPM 31510 advantage in modulating mitochondrial metabolic networks to augment chemotherapeutic efficacy of standard of care in cancer management. Interestingly, priming of mitochondria from BPM 31510 in In vitro and preclinical animal studies provide support for the unparalleled advantage of the BPM 31510 combination in mitigating chemotherapy induced toxicity routinely reported in treatment protocols in advanced solid tumor cases.
Berg technology was also utilized to identify other lead molecule BPM 31543 that contains a calcitriol based technology to prevent chemotherapy-induced alopecia (CIA) currently in Phase I clinical trials at Memorial Sloan Kettering Cancer Center. In addition, preclinical models demonstrate the utility of BPM 31543 in the potential treatment of chemotherapy induced myelosuppression (CIMS). In both clinical indications the endogenous nature of the active molecule in the formulation has led to absence of adverse effects in preclinical models.
Via Krishan Maggon